The 5-year survival rate of lung adenocarcinoma with bone metastasis is less than 5%, and the median survival period is only about 7 months, of course, there are some differences in each person’s situation. Bone metastasis of lung adenocarcinoma suggests that the patient’s condition is more serious, and targeted therapy requires oral or intravenous infusion of targeted drugs under the guidance of doctor. The average life expectancy is about 7 months, which is on the short side. However, there are individual differences in each person’s condition. If the test is positive for the driver gene, targeted therapy can be used to appropriately extend the patient’s life expectancy, which can even reach about two years. Clinically, the fusion gene mutation is called diamond mutation, and after targeted therapy, the survival period of patients can even be extended to 5 years, but this situation is relatively rare in the clinic. However, this kind of situation is relatively rare in clinic. For patients with lung adenocarcinoma who have bone metastasis, it is recommended to consult oncologists in regular hospitals for targeted therapy.